International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Journal: European addiction research

Volume: 24

Issue: 1

Year of Publication: 2018

Affiliated Institutions:  Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Amsterdam Institute of Addiction Research (AIAR), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. University Hospital of Psychiatry, University of Bern, Bern, Switzerland. Karolinska Institutet, Stockholm, Sweden. Columbia University, New York State Psychiatric Institute, New York, New York, USA. ICASA Foundation, University of Amsterdam, Amsterdam, the Netherlands. Eötvös Loránd University, Budapest, Hungary. Department of Pharmacy, University of Limpopo, Sovenga, South Africa. Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. Department of Psychiatry, Radboudumc, Donders Institute for Brain, Cognition and Behavior, Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), Nijmegen, the Netherlands.

Abstract summary 

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.

Authors & Co-authors:  Crunelle Cleo L CL van den Brink Wim W Moggi Franz F Konstenius Maija M Franck Johan J Levin Frances R FR van de Glind Geurt G Demetrovics Zsolt Z Coetzee Corné C Luderer Mathias M Schellekens Arnt A Matthys Frieda F

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Kaye S, Ramos-Quiroga JA, van de Glind G, Levin FR, Faraone SV, Allsop S, Degenhardt L, Moggi F, Barta C, Konstenius M, Franck J, Skutle A, Bu ET, Koeter MW, Demetrovics Z, Kapitány-Fövény M, Schoevers RA, van Emmerik-van Oortmerssen K, Carpentier PJ, Dom G, Verspreet S, Crunelle CL, Young JT, Carruthers S, Cassar J, Fatséas M, Auriacombe M, Johnson B, Dunn M, Slobodin O, van den Brink W. Persistence and dubtype stability of ADHD among substance use disorder treatment seekers. J Atten Disord. 2016 pii:1087054716629217.
Authors :  13
Identifiers
Doi : 10.1159/000487767
SSN : 1421-9891
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
Attention deficit/hyperactivity disorder;Consensus;Diagnosis;Substance use disorders;Treatment
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
Switzerland